Although Gilead Sciences Inc.’s sofosbuvir could make history as the first interferon-free treatment to be approved for hepatitis C, it may face generic competition in India soon after it hits the market because it isn’t innovative enough, according to some advocacy groups. Read More
BEIJING – China’s clinical research organizations (CROs) face a shortage of qualified monitors even as they struggle to find a semblance of stability. Read More
HONG KONG – Fueled in part by proposed policy reforms, biotech and health care stocks in China and Hong Kong bourses have shown signs of life since a very significant meeting of Communist Party leaders in Beijing two weeks ago. Read More
BEIJING – Just a few days after Beigene Co. Ltd.’s CEO and co-founder John Oyler signed a second sizable deal with the Merck Serono arm of Merck KGaA – the up-front payments undisclosed, but with a promise of almost $500 million if all milestones are achieved in both – he admitted the cash removes a layer of stress: “Maybe you sleep better at night, but it’s business as usual. The deal with Merck doesn’t change the way you work or the passion.” Read More
SHANGHAI – The growth of China’s biotech industry may be a more effective channel for talent than any of the myriad government programs to reverse the country’s ongoing brain drain. Read More
